URGN

UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates

UroGen Pharma: Q4 Earnings Insights

UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments

UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline

Jelmyto And UGN-102 Will Likely Drive Strong Returns For UroGen Shareholders

URGN Is Worth $50/Share Should It Trade At Revenue Multiples Consistent With Its Peers

UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference